440 related articles for article (PubMed ID: 21418260)
1. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
[TBL] [Abstract][Full Text] [Related]
2. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
[TBL] [Abstract][Full Text] [Related]
3. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
Kuhn RJ; Gelrud A; Munck A; Caras S
Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
Graff GR; McNamara J; Royall J; Caras S; Forssmann K
Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
[TBL] [Abstract][Full Text] [Related]
6. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
Thorat V; Reddy N; Bhatia S; Bapaye A; Rajkumar JS; Kini DD; Kalla MM; Ramesh H
Aliment Pharmacol Ther; 2012 Sep; 36(5):426-36. PubMed ID: 22762290
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
[TBL] [Abstract][Full Text] [Related]
10. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.
Ramesh H; Reddy N; Bhatia S; Rajkumar JS; Bapaye A; Kini D; Kalla M; Thorat V
Pancreatology; 2013; 13(2):133-9. PubMed ID: 23561971
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of pancrealipase delayed-release capsules (Creon) in patients with pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery].
Vitkomb D; Maleska-Panas E; Lekhman G; Vasil'eva N; Gubergrits N; Karas S; Shen Ia; Sander-Strukmaer S
Eksp Klin Gastroenterol; 2010; (3):65-70. PubMed ID: 20496792
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
Delhaye M; Meuris S; Gohimont AC; Buedts K; Cremer M
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):699-703. PubMed ID: 8853261
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
Sander-Struckmeier S; Beckmann K; Janssen-van Solingen G; Pollack P
Pancreas; 2013 Aug; 42(6):983-9. PubMed ID: 23587850
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.
Morawski JH; Prüfert A; van Engen A; Foerster D; Sander-Struckmeier S; Małecka-Panas E; Pezzilli R
J Med Econ; 2012; 15 Suppl 1():15-25. PubMed ID: 23043594
[TBL] [Abstract][Full Text] [Related]
17. [Experience with the use of 13C-breath test for the evaluation of the efficacy of enzyme substitution therapy with microencapsulated pancreatinin in patients with severe primary pancreatic insufficiency].
Rapoport SI; Maev IV; Kucheriavyĭ IuA; Shubina NA; Semenova NV; Stukova NIu; Archakov AI
Klin Med (Mosk); 2009; 87(1):53-7. PubMed ID: 19256262
[TBL] [Abstract][Full Text] [Related]
18. Effect of Pancrelipase Therapy on Exocrine Pancreatic Insufficiency Symptoms and Coefficient of Fat Absorption Associated With Chronic Pancreatitis.
Barkin JA; Barkin JS
Pancreas; 2021 Feb; 50(2):176-182. PubMed ID: 33560089
[TBL] [Abstract][Full Text] [Related]
19. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
